

Run-in
Prednisone dose
Wash-out
Mepolizumab (750mg)
Placebo
Randomization
Visits
1
2
4
6
8
10
12
14
Weeks
2
6
10
14
18
2
2
26
Starting doses of prednisone
25.0 20.0 15.0 10.0 7.5 5.0
20.0 15.0 10.0 7.5 5.0 5.0
17.5 12.5 7.5 5.0 5.0 5.0
15.0 10.0 7.5 5.0 5.0 5.0
12.5 7.5 5.0 2.5 2.5 2.5
10.0 7.5 5.0 2.5 2.5 2.5
7.5 5.0 2.5 0.0 0.0 0.0
5.0 2.5 0.0 0.0 0.0 0.0

Figure 1




1.0
0.9
0.8
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0.0
Mepolizumab
p=0.003
Placebo
Randomization
0 2 4 6 8 10 12 14 16 18 20 22 24 26
Time to Exacerbation (weeks)
Number at risk
Mepolizumab: 9 9 8 7 7 7 7 7
Placebo: 10 9 7 7 5 4 3 2

Figure 2



Shown are the mean proportions of eosinophils in sputum and numbers of eosinophils in blood at study entry (V1), 4 weeks after the first infusion of a study drug (V4), and at the completion of study treatment (V12) in the two study groups. In the mepolizumab group, one patient was withdrawn because of an adverse event. One patient in the mepolizumab group and nine in the placebo group had an exacerbation before the study was complete. V4 sputum was not obtained from one patient. One patient in the mepolizumab group and one patient in the placebo group were enrolled in the study in error, since they did not have sputum eosinophilia at baseline. The dashed lines indicate normal values.

Figure 3